ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1354	National Cancer Institute	Html	null	Melanoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of melanoma.			CLICK HERE
1430	National Cancer Institute	Html	en	Stomach (Gastric) Cancer Prevention (PDQ®)–Patient Version	Smoking and H. pylori infection are important risk factors for stomach (gastric) cancer. Learn about all of the risk factors for stomach cancer and how to prevent stomach cancer in this expert-reviewed summary.	PDQ Screening 0.364501 cancer risk factors 0.420087 cancer treatment 0.365273 Cancer prevention 0.532051 cancer prevention trials 0.402318 healthy diet 0.359621 cancer protective factor 0.402244 United States 0.45543 prevention clinical trials 0.399973 protective factors 0.416286 antibiotics lowers 0.358249 following PDQ summaries 0.402867 Cancer Information Service 0.393528 PDQ cancer information 0.513502 number 0.358741 Clinical Trials section 0.366407 common cancer 0.369836 Prevention Editorial Board 0.402679 treatment clinical trials 0.365364 dietary supplements 0.383267 H. pylori bacteria 0.36065 National Cancer Institute 0.462669 clinical trials 0.512934	PDQ documents 0.365522 beta carotene 0.388269 health care 0.357632 cancer information summary 0.455266 cancer doctors 0.360396 new treatment 0.364974 breast cancer prevention 0.387351 cancer patients 0.36264 Cancer Care page 0.385527 PDQ database 0.368612 latest published information 0.364412 cancer risk factor 0.42115 NCI’s PDQ 0.372914 PDQ summary 0.382762 NCI PDQ cancer 0.429445 cancer clinical trials 0.401358 stomach cancer 0.900678 risk factors 0.486241 cancer information summaries 0.399032 comprehensive cancer information 0.399493 stomach cancer prevention 0.492255 risk 0.486594	CLICK HERE
1455	National Cancer Institute	Html	en	Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of Merkel cell carcinoma.	inadequate surgical margins 0.329956 cell polyomavirus infection. 0.336356 lymph node dissection 0.348903 Australian Merkel cell 0.385562 Distinct merkel cell 0.383584 neuroendocrine) carcinoma. 0.357189 node-positive Merkel cell 0.37626 Cell Carcinoma Information 0.370356 Ann Surg Oncol 0.393202 Rockville Merkel Cell 0.387174 clinical trials 0.331337 distant metastatic disease 0.331199 newly diagnosed patients 0.336848 cell carcinoma tumors 0.386769 Merkel cell cancer 0.385012 metastatic disease 0.334729 advanced merkel cell 0.38315 patients 0.398223 human Merkel cell 0.391488 Merkel cell polyoma 0.396025 lymph node biopsy 0.394484 sentinel lymph node 0.424128 Merkel tumours 0.360064 Merkel cell carcinomas 0.385298 primary Merkel cell 0.398409	et al. 0.396589 wide local excision 0.340871 case series 0.379017 Arch Dermatol 0.332282 cutaneous Merkel-cell carcinoma 0.356835 PUBMED Abstract 0.359039 adjuvant radiation therapy 0.370608 Invest Dermatol 0.331034 neuroendocrine-merkel cell carcinoma 0.369705 MCC patients 0.350161 Surg Oncol 0.397083 merkel cell carcinoma 0.931809 Abstract 0.399239 Clin Oncol 0.38708 cell polyomavirus sequences 0.331565 Dermatol Surg 0.33595 Carcinoma Group 0.350591 cell carcinoma demographics 0.372267 Trabecular carcinoma 0.351339 cell polyomavirus DNA 0.331118 lymph node 0.427173 cell carcinoma adjuvant 0.368757 merkel cell polyomavirus 0.477468 lymph node metastases 0.330714	CLICK HERE
1538	National Cancer Institute	Html	en	Coenzyme Q10 (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of coenzyme Q10 as a treatment for people with cancer.	cell respiration 0.339879 naturally occurring forms 0.338495 new blood cells 0.340323 United States 0.340183 plasma coenzyme 0.469789 clinical examination 0.347068 cell growth 0.340428 animal immune systems 0.339418 cancer cells 0.357416 above-mentioned human studies 0.339569 follow-up study 0.36193 quinone chemical group 0.341067 breast cancer prognosis. 0.348287 cellular energy production 0.369553 cancer therapy 0.341253 free radical damage 0.357523 dietary supplements 0.352656 blood levels 0.35773 IND application process 0.337121 anthracycline anticancer drug 0.341617 cancer information summary 0.355992 coenzyme q10 0.913438 free radicals 0.338619 anthracycline drug doxorubicin 0.340494	high-dose coenzyme 0.460691 uncontrolled clinical study 0.342321 clinical drug research 0.340343 specific disease prevention 0.33723 breast cancer patients 0.409089 adjuvant therapy 0.341472 animal studies 0.378869 Investigational New Drug 0.337296 important cellular components 0.338608 normal blood levels 0.341607 protective effect 0.341278 radiation therapy 0.379802 high-level coenzyme 0.453918 aerobic energy production 0.337109 Low blood levels 0.340721 indirect anticancer activity 0.337514 lung cancer cells 0.348538 single-dose radiation therapy 0.3393 standard therapy 0.337625 coenzyme Q10. 0.469116 benzoquinone compound 0.3465 follow-up study report 0.341395 original study 0.33952	CLICK HERE
1596	National Cancer Institute	Html	en	Extragonadal Germ Cell Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of extragonadal germ cell tumors.	malignant extragonadal germ 0.298746 malignant tumor cells 0.298137 cancer treatment 0.292355 Cell Tumors Treatment 0.262583 cancer spreads 0.256757 body 0.292404 germ cell tumor 0.536364 following PDQ summaries 0.254729 PDQ cancer information 0.314684 clinical trial search 0.300526 clinical trials 0.586387 blood levels 0.251953 cancer information summary 0.288819 Benign extragonadal germ 0.279683 clinical trial 0.399211 good prognosis group 0.254652 stem cell transplant 0.261231 tumor markers 0.32423 patients 0.268211 treatment clinical trial 0.259833 PDQ Adult Treatment 0.25471 NCI PDQ cancer 0.263605 extragonadal germ cell 0.973537 radiation therapy 0.307388 Treatment Editorial Board 0.266625	poor prognosis group 0.253054 seminoma extragonadal germ 0.342778 General information 0.25607 Serum tumor marker 0.272202 treatment 0.407159 new cancer treatments 0.252812 NCI-supported cancer 0.263007 cancer cells 0.297225 Cancer Information Service 0.252834 treatment clinical trials 0.280785 National Cancer Institute 0.29056 tumor cells 0.30292 new treatment 0.320955 primary tumor 0.264969 prognosis group 0.287143 metastatic tumor 0.274305 blood 0.260611 nonseminoma extragonadal germ 0.343285 germ cell tumors 0.795411 cancer clinical trials 0.308911 cancer information summaries 0.252228 comprehensive cancer information 0.25212 cancer 0.522779 standard treatment 0.259689	CLICK HERE
1603	National Cancer Institute	Html	en	Essiac/Flor Essence (PDQ®)–Health Professional Version	Expert-reviewed information summary about the use of Essiac/Flor Essence as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	cancer treatment 0.476893 breast cancer patient 0.447748 peer-reviewed scientific literature 0.505169 Flor Essence 0.910617 Canada’s Emergency 0.483591 Essiac 0.743648 Emergency Drug Release 0.58138 market Essiac 0.538568 Essiac herbal tonics. 0.550519 Flor Essence tea 0.527471 health conditions 0.443693 Drug Release Program 0.5531 cancer information summary 0.4699 IND application 0.450106 clinical drug research 0.445755 Rheum palmatum L. 0.477337 cancer patients 0.491951 Investigational New Drug 0.44454 National Health 0.471032 New Drug Application 0.442963 Canadian Department 0.469814 four-herb recipe 0.472871 preclinical new drug 0.49467 cancer cell line. 0.452401	Health Protection Branch 0.470254 Essiac herbs 0.554006 United States 0.45534 Human/Clinical Studies section 0.535541 specific disease treatment 0.444683 Indian rhubarb root 0.47211 Flor Essence formulas 0.534076 Trifolium pratense L. 0.442662 health tonics 0.472986 Rumex acetosella L. 0.474473 conventional anticancer treatments 0.463312 human breast cancer 0.444889 Cnicus benedictus L. 0.443598 Essence herbal teas. 0.46868 dietary supplements 0.454376 Royal Cancer Commission 0.448762 Essiac’s safety 0.539442 new drug submission 0.492934 cancer patients. 0.445606 breast cancer 0.462902 Human Prescription Drugs 0.462631 Ulmus fulva Michx. 0.475105 cancer 0.532647 Laboratory/Animal/Preclinical Studies section 0.471204	CLICK HERE
1725	National Cancer Institute	Html	en	Inflammatory Breast Cancer	A fact sheet about the diagnosis and treatment of inflammatory breast cancer (IBC), an uncommon type of cancer in which the breast becomes red, swollen, and warm.	breast cancer talk 0.38738 ongoing clinical trials 0.322108 breast cancer biology 0.384329 Cancer Treatment Research 0.336489 MS. Inflammatory breast 0.412908 clinical trials 0.369256 Post-mastectomy radiation therapy 0.322454 breast size 0.368687 peau d'orange 0.322535 primary inflammatory breast 0.413233 adjuvant therapy 0.323679 inflammatory breast cancers 0.456146 neoadjuvant chemotherapy 0.327114 entire affected breast 0.371358 cancer recurrence 0.326653 radiation therapy 0.339981 Adjuvant systemic therapy 0.323571 Cancer Survival 0.32586 Cancer Journal 0.32501 invasive breast cancers 0.36818 women 0.331101 sponsors clinical trials 0.32312 Breast reconstruction 0.363182 multimodal approach 0.325682 cancer cells 0.367244	Breast Diseases 0.36337 M. Inflammatory breast 0.415692 HER2-positive breast cancer 0.393048 National Cancer Database 0.332281 nci-supported clinical trials 0.33341 National Cancer Institute 0.374989 hormone therapy 0.325328 estrogen-dependent cancer cells 0.336098 breast carcinoma incidence 0.386211 African American women 0.324285 Inflammatory breast tumors 0.439717 lymph vessels 0.32463 cancer detection 0.328538 neoadjuvant HER2-directed therapy 0.322104 inflammatory breast carcinoma 0.435431 dense breast tissue 0.375347 abnormal breast warmth 0.375148 inflammatory breast cancer 0.961199 Swollen lymph nodes 0.324354 cancer clinical trials 0.346503 Clinical Cancer Research 0.336483 postoperative radiation therapy 0.322326 et al 0.375354 cancer patient 0.327473	CLICK HERE
2067	National Cancer Institute	Html	es	Terapia hormonal para el cáncer de seno	Hoja informativa que describe la terapia hormonal y su función en la prevención y tratamiento del cáncer de seno. Incluye información acerca de los efectos secundarios posibles y de los fármacos que pueden interferir con la terapia hormonal.	Surgical Adjuvant Breast 0.34336 Lancet Oncology 0.360626 Sestak I 0.320955 seno her2 y HR 0.354769 endocrine-responsive early breast 0.32332 endocrine therapy 0.324855 Preventing breast 0.319374 advanced breast 0.370204 Adjuvant hormonal therapy 0.333366 Cuzick J 0.320795 Vogel VG 0.310952 as adjuvant treatment 0.327521 efectos agonistas 0.311137 combined survival analysis 0.309596 Pippen J 0.31114 randomized trial comparing 0.312309 Collaborative Group 0.311107 seno hr 0.420398 hormonal therapy 0.348519 PubMed Abstract 0.906244 Surgical Oncology Clinics 0.312057 Clinical Oncology 0.330375 with advanced breast 0.322297 prior endocrine therapy 0.310537 early breast cancer 0.522236	alto riesgo 0.314676 hormonas estrógeno 0.407972 Bowel Project 0.309666 Wickerham DL 0.323539 aromatasa anastrozol 0.350666 initial adjuvant therapy 0.311523 Breast Cancer Group 0.336508 Costantino JP 0.33801 P-2 Trial 0.309919 Bowel Project Study 0.309651 seno er 0.390638 developing invasive breast 0.321634 standard hormonal therapy 0.329685 adjuvant endocrine therapy 0.312843 Italian Tamoxifen Anastrozole 0.312927 breast cancer 0.858969 Breast Cancer Trialists 0.369705 IBIS-I breast 0.319452 Forbes JF 0.31136 enzima llamada 0.312883 tamoxifen treatment 0.320843 Cancer Institute 0.344896 seno her2 0.38128 primary breast 0.320324	CLICK HERE
15584	National Cancer Institute	Html	en	Childhood Cancer Genomics (PDQ®)–Health Professional Version	Expert-reviewed information summary about the genomics of childhood cancer. The summary describes the molecular subtypes for specific pediatric cancers and their associated clinical characteristics, the recurring genomic alterations that characterize each subtype at diagnosis or relapse, and the therapeutic and prognostic significance of the genomic alterations. The genomic alterations associated with brain tumors, kidney tumors, leukemias, lymphomas, sarcomas, and other cancers are discussed.	childhood cancers 0.451916 genomic landscape 0.448565 leukemia cell lines 0.468388 Leukemia Group study 0.460885 Pediatric Acute Myeloid 0.449186 B-cell precursor 0.478228 childhood B-cell precursor 0.465086 B-acute lymphoblastic leukemia 0.506359 poor prognosis 0.440387 mutations 0.5002 children 0.490055 acute lymphoblastic leukaemia 0.700198 specific mutations 0.439289 AML 0.440256 Childhood Acute Lymphoblastic 0.50969 acute lymphoblastic leukemias 0.496998 chromosomal abnormalities 0.446518 CEBPA mutations 0.439533 oncology group study 0.489092 leukemia development 0.4551 B-precursor Acute Lymphoblastic 0.495043 patients 0.462491 prognostic significance 0.476271 Nat Genet 0.458917 Hyperdiploid leukemia cells 0.465322	childhood cancer 0.441528 et al. 0.603959 lymphoblastic leukemia interacts 0.498545 high-risk acute 0.4447 pre-B cell leukemia 0.456422 Pediatr Blood Cancer 0.444419 acute myeloid leukemia 0.542492 Moorman AV 0.468863 acute lymphocytic leukemia 0.496126 acute lymphoblastic leukaemias 0.511116 favorable prognosis 0.439188 point mutations 0.44293 B-acute lymphoblastic leukaemia 0.466866 cases 0.445244 genomic alterations 0.438134 Abstract 0.573806 Clin Oncol 0.509945 favorable outcome 0.455497 blood 0.45817 Acute promyelocytic leukemia 0.495963 pathogenic germline mutations 0.450974 acute lymphoblastic leukemia 0.983229 acute leukemia 0.50127 Mullighan CG 0.471025	CLICK HERE
16834	National Cancer Institute	Html	en	Benefits of Nanotechnology for Cancer	Nanotechnology offers specific benefits that will enable the future of cancer care. Find out here what these benefits are.	red blood cells 0.289952 cancer treatment 0.2825 tumor endothelium barriers 0.421993 tumor blood vessels 0.384277 tumor interstitial fluid 0.381214 leaky vasculature 0.26567 drug delivery 0.676613 relatively large nanoparticles 0.291836 tumor region 0.406678 higher intratumoral accumulation 0.251171 traditional biological barriers 0.261085 nanoparticles 0.370499 negatively charged nanoparticles 0.284913 solid tumor treatment 0.521666 tumor site 0.484864 tumor stroma 0.468242 cancer drug delivery 0.312793 larger tumor mass 0.494058 acidic environment 0.280266 passive tumor accumulation 0.557879 e.g. biological barriers 0.246569 pancreatic cancer therapy 0.239135 tumor endothelium barrier 0.389992 large biological molecules 0.246874 cancer treatment efficacy 0.244109	tumor mass 0.83917 tumor tissue 0.353798 tumor stroma barrier 0.402359 fast growing tumor 0.412482 cancer cells 0.319257 acceptable drug delivery 0.271477 pancreatic cancer 0.267558 generation nanoparticle therapeutics 0.242211 nanoscale devices 0.277755 tumor cells 0.444134 e.g. functional barriers 0.237198 tumor masses 0.357375 Pancreatic cancer stroma 0.2599 interstitial fluid pressure 0.415697 water-insoluble nanoparticles 0.237625 biological barriers 0.281667 nanoparticle ‘passive tumor 0.434599 tumor penetration 0.354635 nanoparticle surface modification 0.243794 pancreatic cancer cell 0.255371 poorly functioning vasculature 0.239508 EPR effect 0.941886 efficient passive tumor 0.412347 tumor microenvironment 0.390631	CLICK HERE